CRESSET BIOMOLECULAR DISCOVERY LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +6.8%

  £6,774,176 → £7,237,532

• Cash

  -56%

  £2,561,175 → £1,126,707

  lowest in 4 filed years

• Net assets

  -45.4%

  £4,250,543 → £2,322,606

• Employees

  -13.9%

  115 → 99

• Operating profit

  +40.1%

  -£4,913,454 → -£2,942,740

• Profit before tax

  +39.6%

  -£4,844,423 → -£2,926,130

• Wages

  +0.2%

  £7,665,072 → £7,683,134

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on a going concern basis, which assumes that Cresset will continue in operational existence for at least twelve months from the date these financial statements are approved. Based on forecasts and stress test scenarios, considering existing funds and the capital raise after the year-end, the Directors determine that Cresset will have sufficient cash for the next twelve months and as such can be considered a going concern.”

Group structure

1. CRESSET BIOMOLECULAR DISCOVERY LIMITED · parent
   1. Cresset Biomolecular Discovery Inc 100% · USA · Development and utilisation of computerised biomolecular modelling
   2. Cresset Biomolecular Discovery (India) Private Limited 100% · India · Development and utilisation of computerised biomolecular modelling

Significant events

• “Cresset acquired Molab.ai GmbH on 18 June 2025, a pioneer in artificial intelligence technologies tailored for molecular research.”
• “Further capital by way of an ordinary share issue of 4,438 shares for consideration of £1,126.68 per share was raised on 14 August 2025 to support the growth plans of the Group.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

10

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.